Articles tagged with Fatty Liver Disease
A new study reveals that liquid fructose intake, even in high-fat diets, can accelerate liver fat accumulation and hypertriglyceridemia. The study found that fructose induces an increase in the synthesis of fatty acids in the liver and inhibits lipid oxidation, leading to the emergence of non-alcoholic fatty liver disease (NAFLD).
Researchers found that long or irregular menstrual cycles in young women are associated with an increased risk of nonalcoholic fatty liver disease (NAFLD). NAFLD is a chronic condition where excess fat builds up in the liver, increasing the risk of death. Lifestyle changes can help reduce the risk of NAFLD in these women.
Research by the University of Queensland found that male livers with hepatic diseases undergo a sex change as part of a self-protective mechanism. The study suggests that this transformation may be driven by the female hormone oestrogen, which helps to slow down disease progression.
NAFLD and diabetes are linked through subclinical inflammation, insulin resistance, and dysregulated liver-derived proteins. Integrating knowledge from childhood to older age can help personalize prevention and treatment.
A nationwide study in Germany found that liver cirrhosis has the highest mortality rate among chronic diseases, with 0.94% of hospital admissions affected. The study also showed a decline in mortality rates due to improvements in Hepatitis C treatment, but an increase in non-alcoholic fatty liver disease cases.
A comprehensive review highlights recently discovered associations between lncRNAs and specific diseases, including fatty liver disease and liver cancer. The study suggests that a diverse group of molecules known as long noncoding RNAs could emerge as biomarkers for liver disease.
Research found that mothers with metabolic syndrome can switch on an imprinted gene in their mice offspring, leading to liver disease. The study suggests a key role for imprinted genes in the development of non-alcoholic fatty liver disease (NAFLD).
A new Chinese Medical Journal study explores the risks of non-alcoholic steatohepatitis (NASH) turning into liver cancer. Early detection through simple medication and lifestyle changes can prevent NAFLD from progressing to more severe conditions, such as cirrhosis and hepatocellular carcinoma.
Researchers found that alterations in the RNF43 and ZNRF3 genes lead to an accumulation of lipids and inflammation in the liver, increasing the risk of developing non-alcoholic steatohepatitis (NASH) and fatty liver disease. These genetic changes also affect liver cell proliferation, contributing to the progression of liver diseases.
A study by Kanazawa University researchers found that the chemokine CCL3 plays a significant role in inducing inflammation as nonalcoholic fatty liver disease develops. The presence of CCL3 increased liver macrophage accumulation, leading to liver inflammation and scarring.
Exercise modifies the adaptation of the liver to increased energy intake, regulating enzymes for glucose and fructose degradation. Regular physical activity also improves glucose control and reduces fat storage in the liver, offering a comprehensive insight into molecular adaptations to high-energy diets.
A new study by Keck Medicine of USC found that food insecurity increases the risk of death among patients with nonalcoholic fatty liver disease and advanced liver disease. The study, which analyzed data from over 34,000 individuals, suggests that eradicating food insecurity could eliminate up to 7% of nonalcoholic fatty liver disease d...
Scientists at Kumamoto University have developed a novel peptide vaccine that improves obesity-related dyslipidemia and may be cost-effective. The vaccine targets angiopoietin-like protein 3 (ANGPTL3) and has been shown to reduce dyslipidemia in mice, producing antibodies that last for six months.
A large-scale epidemiologic study in China identified links between long-term exposure to ambient air pollution and metabolic-associated fatty liver disease (MAFLD). Long-term exposure to air pollution may increase the risk of MAFLD, especially in individuals with unhealthy lifestyles and central obesity.
A team of researchers at UC Davis Health has developed a novel PET imaging-based tool to detect liver inflammation in non-alcoholic fatty liver disease. The tool uses dynamic PET imaging and mathematical modeling to measure glucose transport from blood to liver tissue, allowing clinicians to quantify liver inflammation.
Researchers found that video-based, telehealth-delivered exercise and weight loss programs improved pain and function in people with knee osteoarthritis and overweight or obesity. The intervention with dietary component led to substantial weight loss and additional benefits.
A study found that D-glyceric acid treatment improved metabolism, blood parameters, and reduced low-grade inflammation in healthy volunteers aged 50-60 years. The compound's activation of mitochondrial metabolism may help interrupt the spiral of persistent systemic inflammation and improve liver function.
Researchers found that albino mice with a mutated tyrosinase gene are more susceptible to non-alcoholic steatohepatitis (NASH) than black mice. This study provides new insights into the genetic factors contributing to NASH and its progression.
Researchers have identified a novel estrogen compound that provides benefits similar to hormone replacement therapy but without the risk factors associated with it. The compound has been shown to reduce excess lipid deposition in the liver and prevent the progression of fibrosis, which can lead to liver failure and metabolic problems.
A VCU study found that people with advanced liver scarring caused by obesity and diabetes are dying from liver disease, underscoring the need for new treatments. The research provides a roadmap for future therapies to prevent liver transplants and save lives.
Researchers identified five genes mutated in people with liver disease, affecting insulin sensitivity and fat metabolism. These mutations reduce the liver's ability to respond to dietary sugars and fats.
A new center will address individual, familial, societal and environmental factors contributing to health disparities in the Latino/a/x community. The center will support research projects and interventions aimed at reducing obesity and chronic disease risk in Latino/a/x families.
A multidisciplinary taskforce developed a Clinical Care Pathway for NAFLD/NASH, outlining practical guidance from screening to patient care management. The pathway aims to provide efficient, safe, and value-based care for patients with NAFLD and NASH, highlighting the importance of early interventions and shared decision-making.
A new study found that every extra 1cm in waist circumference increases the odds of advanced fibrosis by 5% in people with type 2 diabetes. Advanced fibrosis is a late stage of non-alcoholic fatty liver disease (NAFLD), which can lead to serious liver damage.
Researchers found that DNA methylation patterns at specific genomic sites correlated with levels of fibrosis in non-alcoholic fatty liver disease (NAFLD). The study suggests that these patterns could be used to diagnose the severity of this condition, potentially leading to earlier treatment and improved outcomes.
A 34-year follow-up study found that the coexistence of hypertension and fatty liver disease did not exceed their separate effects on mortality. The study suggests a negative interaction between the two conditions on cardiovascular death in non-diabetic men.
A comprehensive review reveals how excessive fructose intake can disrupt metabolic pathways, leading to diseases such as diabetes, fatty liver disease, and heart disease. The study highlights the role of protein transporters, gluconeogenesis, and gene-level changes in regulating fructose metabolism.
A new study by Salk scientists found that time-restricted eating (TRE) confers multiple health benefits, including reduced risk of type 2 diabetes, fatty liver disease, and sepsis, regardless of age and sex. TRE may also protect against infectious diseases like COVID-19 and improve insulin resistance.
Researchers at Skoltech have discovered structures called apical bulkheads in liver cells that are responsible for the narrow shape of bile canaliculi. The discovery reveals a key role for the Rab35 protein in regulating hepatocyte lumina formation and suggests potential avenues for medical applications in fatty liver disease and fibrosis
Researchers linked World Trade Center dust exposure to increased risk of liver disease in responders. Analysis of lung scans found evidence of hepatic steatosis, a condition associated with chemical exposures.
Patients with obesity or type 2 diabetes are at a higher risk of developing NAFLD and NASH. Effective screening, diagnosis, and treatment strategies are urgently needed for this growing population.
A novel 3D imaging technique reveals the degeneration of nerves in the liver, correlating with the severity of liver pathology in non-alcoholic fatty liver disease. The study suggests a 'vicious cycle' where compromised nerve function contributes to disease progression and worsens metabolic challenges.
Researchers found that a chemical modification called m6A may offer protection against non-alcoholic fatty liver by slowing down the accumulation of fat in the liver. The study also suggested that this modification occurs at a different rate in females than males, potentially explaining sex differences in liver fat content.
A new noninvasive biomarker, thrombospondin-2, can identify patients at risk of NAFLD complications using a simple blood test. The biomarker was found to parallel clinical indicators used to categorize pathological changes in liver cells.
A two-year study found that testosterone therapy normalised testosterone levels, reduced NAFLD, and suppressed symptoms of hypogonadism in obese men. Testosterone therapy may help obese men with functional hypogonadism and type-2 diabetes reduce the prevalence of non-alcoholic fatty liver disease.
A new study found that blocking ABCB10 protein in liver cells protects against insulin resistance and fatty liver disease. Increased bilirubin content inside mitochondria driven by ABCB10 activity contributes to fatty liver disease. The findings could inspire the development of therapies targeting ABCB10 or mitochondrial bilirubin.
A team of scientists at Cincinnati Children's Hospital Medical Center has discovered a promising new approach to preventing obesity-driven liver damage. By controlling a subgroup of immune system cells that trigger non-alcoholic fatty liver disease (NAFLD), researchers have identified a potential treatment target.
A new registry study linked non-alcoholic fatty liver (NAFLD) to a 17-fold increased risk of liver cancer, particularly hepatocellular carcinoma. NAFLD patients were also found to have a higher risk of other cancers, emphasizing the need for targeted interventions and personalized screening strategies.
Researchers developed a chimeric mouse model that accurately reproduces human non-alcoholic fatty liver disease (NAFLD) by combining both human and murine cells. The study reveals striking differences in liver cell behavior, metabolism, and gene expression, providing new insights into the disease's mechanisms.
A study published in International Journal of Environmental Research and Public Health found that exercise can alter the oral environment, favoring less harmful bacteria in people with NAFLD and gum disease. This shift may help reduce inflammation and improve overall health outcomes.
Researchers at the University of Tsukuba found that exercise regimen reduced liver steatosis by 9.5%, liver stiffness by 6.8%, and FibroScan-AST Score by 16.4%. Exercise preserved muscle mass, independent of weight loss, and induced anti-inflammatory responses.
A review of studies links excessive fructose intake to NAFLD in children, suggesting restricting added sugars may reduce risk; current diagnosis methods are inadequate, and better tools are needed.
Researchers at Tokyo University of Science have developed a new method to quantify fat content in liver tissue using near-infrared hyperspectral imaging. The study found that this technique can accurately visualize lipid distributions within the liver and identify fatty liver-associated liver diseases, including cancer.
A new study from the University of Minnesota Medical School suggests that disease-driving B cells contribute to the development of non-alcoholic fatty liver disease (NAFLD). The research, led by Fanta Barrow, found that a Western diet and changes in gut microbes activate these pathogen-fighting B cells into 'disease-promoters',
Researchers have identified CNNM4 protein as key regulator of magnesium in the liver and potential therapeutic target for non-alcoholic fatty liver disease. High expression of CNNM4 protein is associated with inflammation and liver fibrosis in patients with non-alcoholic steatohepatitis.
Researchers developed a stem cell-based cell culture model for nonalcoholic fatty liver disease (NAFLD), revealing key findings on gene expression, lipid droplet morphology, and metabolic networks. The model also showed promising results with AdipoRon, a synthetic analogue that positively influences hepatocyte metabolism.
A study published in the American Journal of Roentgenology found that multiparametric CT findings can distinguish patients with high-risk NAFLD, characterized by advanced fibrosis or cirrhosis. However, the presence of nonalcoholic steatohepatitis (NASH) remains elusive on CT.
The study found that the green Mediterranean diet resulted in the greatest reduction of hepatic fat, with participants experiencing dramatic reductions in fatty liver. The modified diet included high intake of walnuts and Mankai, as well as less red meat.
Researchers found that a protein called Cx43 allows stress signals from one liver cell to spread to neighboring cells, causing dysfunction. Mice with deleted Cx43 were protected from insulin resistance, glucose intolerance, and non-alcoholic fatty liver disease.
A new study suggests a link between low levels of glycine and nonalcoholic fatty liver disease (NAFLD), potentially leading to novel treatment options. Researchers found that improving body composition and glutathione synthesis with a tripeptide called DT-109 could attenuate experimental NAFLD.
Researchers found that triclosan disrupts metabolism and the gut microbiome, leading to accelerated development of fatty liver and fibrosis. The study provides new insights into risk factors for non-alcoholic fatty liver disease (NAFLD) in humans.
Researchers will investigate the role of Cyp2b genes, human CYP2B6 gene, and environmental toxicants like PFOS in obesity and fatty liver disease. The study aims to understand complex interactions between diet, fat stores, and genetic factors.
A recent study by University of Jyväskylä researchers found that a dietary supplement increased the growth of good bacteria in rats' gut, leading to reduced liver fat content and improved glucose metabolism. Preliminary results from human studies with fatty liver disease patients also seem promising.
A nationwide cohort study has confirmed that non-alcoholic fatty liver disease (NAFLD) is associated with increased mortality risk, even in mild stages. The study found that patients with NAFLD had a 93% increased risk of all-cause mortality, driven primarily by deaths from extra-hepatic cancer and cirrhosis.
Yale researchers found a molecular connection between nonalcoholic fatty liver disease and liver insulin resistance. They identified diacylglycerols and ceramides as key players in this process.
A new study found that obesity-related illnesses frequently occur in people with a BMI over 30, yet only 9% had obesity recorded as a cause of death. Researchers argue that obesity is not being accurately documented on medical certificates, highlighting the need for further studies.
A pilot study found that assessing liver fibrosis in people with type 2 diabetes could identify large numbers of previously undiscovered cases of advanced liver disease, increasing diagnosis rates 5-fold. The study also discovered that over half of patients diagnosed with significant fibrosis had normal ALT levels.
Children born to obese mothers face higher risk of developing non-alcoholic fatty liver disease due to microbiome disruption, which can be influenced by maternal diet during pregnancy. The study aims to investigate the role of pyrroloquinoline quinone in improving the microbiome and lowering the risk for NAFLD.
A study published in JCI Insight has identified a potential treatment for non-alcoholic fatty liver disease (NAFLD), with tesamorelin reducing liver fat and fibrosis progression. The drug appears to increase expression of genes associated with burning of fat in the mitochondria, which may prevent fibrosis.
New studies demonstrate significant reductions in ALT, hepatic fat, and liver damage biomarkers for patients with non-alcoholic steatohepatitis (NASH). The treatments target lipid metabolism and show potential to address type 2 diabetes and obesity.